• Remon Korenblik, Jan Heil, Jens Smits, Sinead James, Bram Olij, Wolf O Bechstein, BemelmansMarc H AMHADepartment of Surgery, Maastricht University Medical Centre, Maastricht, the Netherlands.Department of General, Visceral and Transplant Surgery, University Hospital Aachen, Aachen, Germany., Christoph A Binkert, Stefan Breitenstein, Michael Williams, Olivier Detry, Maxime J L Dewulf, Alexandra Dili, Lukasz F Grochola, Jon Grote, Daniel Heise, Jennifer A Kalil, Peter Metrakos, Ulf P Neumann, Sam G Pappas, Francesca Pennetta, Andreas A Schnitzbauer, Jordan C Tasse, Bjorn Winkens, Olde DaminkSteven W MSWMDepartment of Surgery, Maastricht University Medical Centre, Maastricht, the Netherlands.Department of General, Visceral and Transplant Surgery, University Hospital Aachen, Aachen, Germany.NUTRIM-School of Nutrition and Translation, Christiaan van der Leij, Erik Schadde, Ronald M van Dam, and DRAGON trials collaborative .
• GROW-School for Oncology and Reproduction, Maastricht University, Maastricht, the Netherlands.
• Br J Surg. 2024 Apr 3; 111 (4).

BackgroundThe purpose of this study was to compare 3-year overall survival after simultaneous portal (PVE) and hepatic vein (HVE) embolization versus PVE alone in patients undergoing liver resection for primary and secondary cancers of the liver.MethodsIn this multicentre retrospective study, all DRAGON 0 centres provided 3-year follow-up data for all patients who had PVE/HVE or PVE, and were included in DRAGON 0 between 2016 and 2019. Kaplan-Meier analysis was undertaken to assess 3-year overall and recurrence/progression-free survival. Factors affecting survival were evaluated using univariable and multivariable Cox regression analyses.ResultsIn total, 199 patients were included from 7 centres, of whom 39 underwent PVE/HVE and 160 PVE alone. Groups differed in median age (P = 0.008). As reported previously, PVE/HVE resulted in a significantly higher resection rate than PVE alone (92 versus 68%; P = 0.007). Three-year overall survival was significantly higher in the PVE/HVE group (median survival not reached after 36 months versus 20 months after PVE; P = 0.004). Univariable and multivariable analyses identified PVE/HVE as an independent predictor of survival (univariable HR 0.46, 95% c.i. 0.27 to 0.76; P = 0.003).ConclusionOverall survival after PVE/HVE is substantially longer than that after PVE alone in patients with primary and secondary liver tumours.© The Author(s) 2024. Published by Oxford University Press on behalf of BJS Foundation Ltd.

22 keywords...

hide…